Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BAX Stock Forecast 2026-2027
$22.46
Current Price
$11.60B
Market Cap
Buy 2
Hold 11
Sell 1
Wall St Analyst Ratings
Distance to BAX Price Targets
+78.1%
To High Target of $40.00
-13.2%
To Median Target of $19.50
-24.3%
To Low Target of $17.00
BAX Price Momentum
-0.8%
1 Week Change
+10.6%
1 Month Change
-24.4%
1 Year Change
+17.5%
Year-to-Date Change
-27.9%
From 52W High of $31.15
+42.8%
From 52W Low of $15.73
📊 TOP ANALYST CALLS
Did BAX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Baxter is one of their latest high-conviction picks.
Latest BAX Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, BAX has a neutral consensus with a median price target of $19.50 (ranging from $17.00 to $40.00). The overall analyst rating is Buy (6.3/10). Currently trading at $22.46, the median forecast implies a -13.2% downside. This outlook is supported by 2 Buy, 11 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BAX Analyst Ratings
2
Buy
11
Hold
1
Sell
BAX Price Target Range
Low
$17.00
Average
$19.50
High
$40.00
Current: $22.46
Latest BAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 6, 2026 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $24.00 |
| May 28, 2026 | Citigroup | Sell | Downgrade | $N/A | |
| May 4, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Apr 6, 2026 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Mar 11, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Feb 17, 2026 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Feb 13, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Jan 9, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Dec 2, 2025 | Morgan Stanley | Underweight | Maintains | $N/A | |
| Oct 31, 2025 | Citigroup | Neutral | Maintains | $N/A | |
| Oct 31, 2025 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Oct 31, 2025 | UBS | Neutral | Maintains | $N/A | |
| Oct 31, 2025 | Argus Research | Hold | Downgrade | $N/A | |
| Oct 7, 2025 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Aug 4, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Aug 4, 2025 | Stifel | Hold | Downgrade | $N/A | |
| Aug 4, 2025 | UBS | Neutral | Maintains | $N/A | |
| Aug 1, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Jul 15, 2025 | Morgan Stanley | Underweight | Maintains | $N/A | |
| Jul 9, 2025 | Citigroup | Neutral | Maintains | $N/A |
Baxter International Inc (BAX) Competitors
The following stocks are similar to Baxter based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Baxter International Inc (BAX) Financial Data
Baxter International Inc has a market capitalization of $11.60B with a P/E ratio of 86.3x. The company generates $11.32B in trailing twelve-month revenue with a -9.7% profit margin.
Revenue growth is +2.9% quarter-over-quarter, while maintaining an operating margin of +6.0% and return on equity of -15.0%.
Valuation Metrics
Market Cap
$11.60B
Enterprise Value
$18.99B
P/E Ratio
86.3x
PEG Ratio
-0.8x
Price/Sales
1.0x
Growth & Margins
Revenue Growth (YoY)
+2.9%
Gross Margin
+33.0%
Operating Margin
+6.0%
Net Margin
-9.7%
EPS Growth
+2.9%
Financial Health
Cash/Price Ratio
+17.4%
Current Ratio
1.9x
Debt/Equity
161.0x
ROE
-15.0%
ROA
+2.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Baxter International Inc (BAX) Business Model
About Baxter International Inc
What They Do
Healthcare company providing essential medical products.
Business Model
The company generates revenue by supplying a wide range of medical products and therapies needed in various healthcare settings, including hospitals and home care. Their offerings include dialysis treatments, intravenous solutions, and surgical products, which cater to both acute and chronic patient needs.
Additional Information
Baxter International Inc. is headquartered in Deerfield, Illinois, and plays a significant role in the global medical products market, serving healthcare providers and patients with innovative solutions for critical care and recovery.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
37,500
CEO
Mr. Andrew P. Hider
Country
United States
IPO Year
1981
Website
www.baxter.comBaxter International Inc (BAX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
WST Stock Up Nearly 33% YTD: Will the Uptrend Continue in the Rest of 2026?
WST has surged nearly 33% YTD as strong earnings, GLP-1 demand and biologics growth fuel momentum that could extend through 2026.
Jul 03, 2026
By Zacks Equity Research
Analyst Blog
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.
Jun 30, 2026
By Ahan Chakraborty
Analyst Blog Plus
Latest News
Quick Summary
Baxter International Inc. will host a conference call on July 30, 2026, at 7:30 a.m. CT to discuss Q2 2026 financial results. Pre-registration is required via their event link.
Why It Matters
Baxter's upcoming conference call will provide insights into its Q2 2026 performance, influencing market sentiment and investment decisions based on financial results and future guidance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Baxter International Inc. (NYSE:BAX) released its 2025 Sustainability Report, detailing progress in its sustainable business practices and commitment to creating long-term stakeholder value.
Why It Matters
Baxter's focus on sustainability and long-term value creation can enhance its reputation and attract socially responsible investors, potentially impacting stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
BAX stock rises as Synovis MCA secures a multi-year agreement to globally commercialize MediThinQ's SHIYA 3D surgical visualization platform.
Why It Matters
BAX's partnership with Synovis MCA to commercialize a new surgical platform may enhance revenue growth and market presence, positively impacting its stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
BAX is implementing a turnaround strategy supported by innovation, strong demand, and AI integration, although it faces regulatory risks and margin pressures.
Why It Matters
BAX's turnaround efforts, driven by innovation and AI, indicate potential growth and resilience, which could enhance investor confidence despite existing regulatory and margin challenges.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Baxter International Inc. (BAX) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, providing insights into its business strategies and outlook for 2026.
Why It Matters
Baxter's presentation at a major healthcare conference signals potential insights into its growth strategy and market positioning, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Earnings beats are particularly significant for stocks that have previously underperformed or been abandoned by the market.
Why It Matters
Earnings beats in previously overlooked stocks can signal a potential turnaround, attracting investor interest and driving stock prices higher.
Source: Market Watch
Market Sentiment:
Positive
Frequently Asked Questions About BAX Stock
What is Baxter International Inc's (BAX) stock forecast for 2027?
Based on our analysis of 6 Wall Street analysts, Baxter International Inc (BAX) has a median price target of $19.50. The highest price target is $40.00 and the lowest is $17.00.
Is BAX stock a good investment in 2027?
According to current analyst ratings, BAX has 2 Buy ratings, 11 Hold ratings, and 1 Sell ratings. The stock is currently trading at $22.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BAX stock?
Wall Street analysts predict BAX stock could reach $19.50 in the next 12 months. This represents a -13.2% decrease from the current price of $22.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Baxter International Inc's business model?
The company generates revenue by supplying a wide range of medical products and therapies needed in various healthcare settings, including hospitals and home care. Their offerings include dialysis treatments, intravenous solutions, and surgical products, which cater to both acute and chronic patient needs.
What is the highest forecasted price for BAX Baxter International Inc?
The highest price target for BAX is $40.00 from at , which represents a 78.1% increase from the current price of $22.46.
What is the lowest forecasted price for BAX Baxter International Inc?
The lowest price target for BAX is $17.00 from at , which represents a -24.3% decrease from the current price of $22.46.
What is the overall BAX consensus from analysts for Baxter International Inc?
The overall analyst consensus for BAX is neutral. Out of 6 Wall Street analysts, 2 rate it as Buy, 11 as Hold, and 1 as Sell, with a median price target of $19.50.
How accurate are BAX stock price projections?
Stock price projections, including those for Baxter International Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 10, 2026 6:13 AM UTC